Druggability & Clinical Context
Druggability
Low
Score: 0.33
Target Class
Signaling Protein
Druggability Analysis
Structural Tractability0.70
Key Metrics
PDB Structures:
6
Known Drugs:
4
Approved:
0
In Clinical Trials:
0
Drug Pipeline (4 compounds)
2 Preclinical
Therapeutic Areas:Neurodevelopmental disorders (lissencephaly, neuronal migration defects) Cognitive impairment and intellectual disability Schizophrenia and psychiatric disorders Alzheimer's disease and neurodegeneration Autism spectrum disorder Cerebellar ataxia
Druggability Rationale: The druggability of RELN for neurodegeneration appears challenging due to its complex signaling mechanism and limited direct small molecule targeting options. While preclinical research suggests potential therapeutic approaches through receptor agonists (VLDLR/ApoER2) or downstream pathway modulators, the lack of high-resolution structural data and clinically validated interventions currently constrains direct pharmaceutical development. The most promising near-term strategies likely involve recombinant protein approaches or indirect signaling cascade enhancements rather than traditional small molecule inhibition/activation.
Mechanism: Drugs targeting RELN would primarily work by enhancing reelin expression or signaling through its receptors (VLDLR and ApoER2) to promote neuronal migration, synaptic plasticity, and cognitive function. Alternatively, pathway modulators could enhance downstream signaling cascades (Dab1-mediated pathways) to compensate for reelin deficiency or dysfunction.
Drug Pipeline (4 compounds)
2 Preclinical
Known Drugs:Leptin (recombinant) (research) โ Reelin pathway modulation in neurological disorders
VPS34 inhibitors (e.g., SAR405) (preclinical) โ Autophagy regulation affecting reelin signaling
SorLA/LR11 modulators (research) โ Reelin receptor trafficking and synaptic plasticity
VLDLR agonists (preclinical) โ Reelin receptor activation for neuronal migration disorders
Structural Data:PDB (6) โAlphaFold โCryo-EM โ
Binding Pocket Analysis:RELN lacks a traditional small-molecule binding pocket as a secreted glycoprotein; structural data (PDB IDs: 2E26, 3A7Q, 5B4X, 6A48, 7LYU) likely reveal receptor-binding epitopes and protein-protein interaction domains suitable for antibody or peptide-based therapeutics rather than conventional ligand binding sites. Drug development strategies favor allosteric modulation through receptor activation or enhancement of Dab1-mediated downstream signaling cascades.
Selectivity & Safety Considerations
Selectivity challenges arise from RELN's broad expression in the CNS and its interaction with multiple receptors (VLDLR, ApoER2, integrin ฮฑ3ฮฒ1), potentially limiting isoform-specific targeting. Off-target effects may occur through modulation of related lipoprotein receptor pathways or autophagy processes when using indirect pathway modulators.
Clinical Trials (9)
Relevant trials from ClinicalTrials.gov
By Phase
NA: 5 ยท PHASE4: 2 ยท Unknown: 2
NA
NCT06876051
n=162
Stress, Relaxation, Breastfeeding
Interventions: Relaxation & Breastfeeding Education, Active comparator, control group
Sponsor: National and Kapodistrian University of Athens
NA
NCT05607654
n=60
Treatment-resistant Depression
Interventions: active iTBS, sham rTMS
Sponsor: First Affiliated Hospital of Zhejiang University
NA
NCT05927129
n=90
Depressive Disorder
Interventions: Antidepressant, Psychotherapy IPT, The combination of antidepressant and IP
Sponsor: First Affiliated Hospital of Zhejiang University
Unknown
NCT01237158
n=140
Bipolar Disorder
Sponsor: University of Sao Paulo
PHASE4
NCT03347890
n=70
Obesity
Interventions: Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml
Sponsor: Zoltan Pataky
NA
NCT05777876
n=400
Treatment-Resistant Depression
Interventions: non-invasive transcranial deep brain sti, Sham stimulation, Motor cortex stimulation
Sponsor: First Affiliated Hospital of Zhejiang University
NA
NCT06881030
n=45
Treatment Resistant Depression (TRD)
Interventions: Noninvasive transcranial magnetic stimul, Noninvasive transcranial magnetic stimul, Sham
Sponsor: First Affiliated Hospital of Zhejiang University
Unknown
NCT01362478
n=120
Schizophrenia
Sponsor: Taipei Medical University WanFang Hospital